98%
921
2 minutes
20
Background: Over the last 2 decades, medical providers have increasingly prescribed pharmaceutical opioids for chronic non-cancer pain, while opioid overdose death rates have quadrupled. Naloxone, an opioid antagonist, can be prescribed to patients with chronic pain to reverse an opioid overdose, yet little is known about how patients perceive this emerging practice.
Objective: This study assessed the knowledge and attitudes toward naloxone prescribing among non-cancer patients prescribed opioids in primary care.
Design: Qualitative study design using semi-structured interviews.
Participants: Adults (N = 24) prescribed high-dose (≥100 morphine mg equivalent daily dose) chronic opioid therapy in eight primary care internal medicine, family medicine and HIV practices in three large Colorado health systems.
Approach: Inductive and deductive methods were used to analyze interview transcripts.
Key Results: Themes emerged related to knowledge of and benefits, barriers and facilitators to naloxone in primary care. Patients reported receiving limited education about opioid medication risks from providers and limited knowledge of naloxone. When provided with a description of naloxone, patients recognized its ability to reverse overdoses. In addition to pragmatic barriers, such as medication cost, barriers to naloxone acceptance included the perception that overdose risk stems from medication misuse and that providers might infer that they were misusing their opioid medication if they accepted a naloxone prescription, prompting an opioid taper. Facilitators to the acceptance of naloxone included medical providers' using empowering, non-judgmental communication practices, framing naloxone for use in "worst case scenarios" and providing education and training about opioids and naloxone.
Conclusions: While patients recognized the utility of naloxone prescribing, we identified important barriers to patient acceptance of naloxone prescribing. To improve the naloxone prescribing acceptability in primary care practice, medical providers and health systems may need to enhance patient education, employ empowering, non-judgmental communication styles and adequately frame discussions about naloxone to address patients' fears.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331002 | PMC |
http://dx.doi.org/10.1007/s11606-016-3895-8 | DOI Listing |
Perm J
September 2025
Department of Pharmacy, Kaiser Permanente Georgia, Atlanta, GA, USA.
Background: Opioids are highly effective for pain management but carry risks. Naloxone quickly reverses opioid overdoses by blocking opioid receptors in the brain. Despite its effectiveness, naloxone remains underutilized.
View Article and Find Full Text PDFJ Opioid Manag
September 2025
St. John's Newfoundland and Labrador, St. John's, NL, Canada.
Objective: To report the rate of prescription opioid use rates over a 5-year period for the population of Newfoundland and Labrador (NL), Canada, and to highlight patient demographics within this cohort.
Design: This retrospective cohort design used population-based pharmacy network prescription data from the province of NL to identify patients who were prescribed opioids from June 1, 2017, to June 1, 2022.
Setting: A cohort of adult and pediatric patients who were being prescribed opioids from June 1, 2017, to June 1, 2022, in NL.
J Opioid Manag
September 2025
University of Arizona, College of Medicine, Phoenix, Arizona.
Pain and addiction are persistent public health issues that can lead to serious and fatal consequences on individuals, families, and communities. With the continued development of the opioid epidemic and the subsequent rise in opioid use and misuse, it is important to recognize the need for intervention at a public health level. Opioid stewardship programs (OSPs) are promising public health interventions that aim to coordinate safe and effective pain management through evidence-based intervention strategies.
View Article and Find Full Text PDFJ Appl Toxicol
August 2025
Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Typical prescribed opioids are known to inhibit intestinal transit and induce emesis-like behaviors in animals via distinct mechanisms and varying magnitudes. However, there is limited evidence regarding whether atypical opioids also produce these adverse effects in animals. This study was designed to investigate whether tramadol, its active metabolite O-desmethyltramadol (M1), and methadone cause such side effects and to elucidate their underlying mechanisms.
View Article and Find Full Text PDFAlcohol Alcohol
July 2025
Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, ON M5B 1W8, Canada.
Introduction: Despite a high prevalence of alcohol use disorder (AUD) in Canada, access to medication-based treatment remains poor. Therefore, our aim was to explore patterns of alcohol toxicity deaths in Ontario, Canada, circumstances surrounding death, prior healthcare interactions, and pharmacotherapy for AUD.
Methods: We conducted a population-based repeated cross-sectional study of alcohol toxicity deaths occurring between 1 January 2018 and 30 June 2022 in Ontario, Canada.